Corporate Member Update-Seagen- Tivdak™ (tisotumab vedotin-tftv)

Introducing a New Treatment Option for Previously Treated Recurrent or Metastatic Cervical Cancer

Seagen would like to announce the approval of Tivdak™ (tisotumab vedotin-tftv) for injection 40 mg, for intravenous use, by the U.S. Food and Drug Administration (FDA) on September 20, 2021. Tivdak is a tissue factor-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this
indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

To read the full press release, please click here.